流式细胞术的疫苗应用。
Vaccine applications of flow cytometry.
机构信息
Department of Laboratory Medicine, University of Washington, Seattle, WA 98195, USA.
出版信息
Methods. 2012 Jul;57(3):383-91. doi: 10.1016/j.ymeth.2012.01.001. Epub 2012 Jan 10.
Abstract
Highly effective vaccines have yet to be identified for many widespread infectious diseases including HIV, tuberculosis and malaria. Many vaccine candidates for these diseases have been designed to induce both cellular and humoral immunity, and measurement of the induced cellular immune response and antibody response is critical for monitoring immunogenicity. The flow cytometric intracellular cytokine staining assay is one of the primary assays for enumerating vaccine-induced T cells in vaccine clinical trials. The assay is flexible, allowing for measurement of various cytokines or functions and phenotyping markers, and the assay can be validated. Changes in other cell types such as innate immune cells are monitored by flow cytometric phenotyping assays. Cell sorting of vaccine-induced T cells and B cells is used to allow genomic and transcriptional analysis of these cells. Thus, flow cytometric methods are commonly used in trials testing the next generation of vaccines.
摘要
目前，仍有许多广泛流行的传染病（包括艾滋病毒、结核病和疟疾）没有有效的疫苗。这些疾病的许多候选疫苗旨在诱导细胞和体液免疫，而诱导的细胞免疫应答和抗体应答的测量对于监测免疫原性至关重要。流式细胞术细胞内细胞因子染色分析是疫苗临床试验中计数疫苗诱导 T 细胞的主要分析方法之一。该分析方法灵活，可用于测量各种细胞因子或功能和表型标志物，并且可以进行验证。通过流式细胞术表型分析来监测其他细胞类型（如固有免疫细胞）的变化。疫苗诱导的 T 细胞和 B 细胞的细胞分选用于允许对这些细胞进行基因组和转录组分析。因此，流式细胞术方法常用于下一代疫苗的临床试验。
相似文献
1
Vaccine applications of flow cytometry.
Methods. 2012 Jul;57(3):383-91. doi: 10.1016/j.ymeth.2012.01.001. Epub 2012 Jan 10.
2
Analyzing cellular immunogenicity in vaccine clinical trials: a new statistical method including non-specific responses for accurate estimation of vaccine effect.
J Immunol Methods. 2020 Feb;477:112711. doi: 10.1016/j.jim.2019.112711. Epub 2019 Dec 3.
3
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis.
Lancet. 2008 Nov 29;372(9653):1894-1905. doi: 10.1016/S0140-6736(08)61592-5. Epub 2008 Nov 13.
4
Poly(I:C) Potentiates T Cell Immunity to a Dendritic Cell Targeted HIV-Multiepitope Vaccine.
Front Immunol. 2019 Apr 24;10:843. doi: 10.3389/fimmu.2019.00843. eCollection 2019.
5
SWIFT clustering analysis of intracellular cytokine staining flow cytometry data of the HVTN 105 vaccine trial reveals high frequencies of HIV-specific CD4+ T cell responses and associations with humoral responses.
Front Immunol. 2024 Jun 6;15:1347926. doi: 10.3389/fimmu.2024.1347926. eCollection 2024.
6
Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses.
PLoS One. 2010 Feb 2;5(2):e9015. doi: 10.1371/journal.pone.0009015.
7
Pushing the frontiers of T-cell vaccines: accurate measurement of human T-cell responses.
Expert Rev Vaccines. 2012 Dec;11(12):1459-70. doi: 10.1586/erv.12.125.
8
Development of an automated analysis system for data from flow cytometric intracellular cytokine staining assays from clinical vaccine trials.
Cytometry A. 2008 Sep;73(9):847-56. doi: 10.1002/cyto.a.20600.
9
Oral immunization with a live coxsackievirus/HIV recombinant induces gag p24-specific T cell responses.
PLoS One. 2010 Sep 2;5(9):e12499. doi: 10.1371/journal.pone.0012499.
10
Broad and potent cellular and humoral immune responses after a second late HIV-modified vaccinia virus ankara vaccination in HIV-DNA-primed and HIV-modified vaccinia virus Ankara-boosted Swedish vaccinees.
AIDS Res Hum Retroviruses. 2014 Mar;30(3):299-311. doi: 10.1089/AID.2013.0149. Epub 2013 Nov 15.
引用本文的文献
1
Generalized linear modeling of flow cytometry data to analyze immune responses in tuberculosis vaccine research.
NPJ Syst Biol Appl. 2025 Aug 10;11(1):90. doi: 10.1038/s41540-025-00572-4.
2
The Application of Single-Cell Technologies for Vaccine Development Against Viral Infections.
Vaccines (Basel). 2025 Jun 26;13(7):687. doi: 10.3390/vaccines13070687.
3
Evaluation of two commercial IBR marker vaccines against in water buffalo ().
Front Vet Sci. 2025 May 7;12:1574794. doi: 10.3389/fvets.2025.1574794. eCollection 2025.
4
Mini-review on the therapeutic vaccines targeting chronic infectious diseases: Evaluation system of therapeutic vaccines targeting HPV and EBV-related cancers.
Hum Vaccin Immunother. 2025 Dec;21(1):2457187. doi: 10.1080/21645515.2025.2457187. Epub 2025 Feb 16.
5
Imaging flow cytometry reveals the mechanism of equine arteritis virus entry and internalization.
Sci Rep. 2025 Jan 25;15(1):3246. doi: 10.1038/s41598-025-87080-x.
6
Applications of Flow Cytometry in Drug Discovery and Translational Research.
Int J Mol Sci. 2024 Mar 29;25(7):3851. doi: 10.3390/ijms25073851.
7
Immune monitoring of SARS-CoV-2-specific T cell and B cell responses in patients with multiple sclerosis treated with ocrelizumab.
Front Immunol. 2023 Sep 20;14:1254128. doi: 10.3389/fimmu.2023.1254128. eCollection 2023.
8
Evaluation of Cellular Immune Response to Adeno-Associated Virus-Based Gene Therapy.
AAPS J. 2023 Apr 26;25(3):47. doi: 10.1208/s12248-023-00814-5.
9
Baseline host determinants of robust human HIV-1 vaccine-induced immune responses: A meta-analysis of 26 vaccine regimens.
EBioMedicine. 2022 Oct;84:104271. doi: 10.1016/j.ebiom.2022.104271. Epub 2022 Sep 27.
10
Mechanisms of Particles in Sensitization, Effector Function and Therapy of Allergic Disease.
Front Immunol. 2020 Jun 30;11:1334. doi: 10.3389/fimmu.2020.01334. eCollection 2020.
本文引用的文献
1
A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204).
PLoS One. 2011;6(8):e21225. doi: 10.1371/journal.pone.0021225. Epub 2011 Aug 3.
2
HIV-DNA priming alters T cell responses to HIV-adenovirus vaccine even when responses to DNA are undetectable.
J Immunol. 2011 Sep 15;187(6):3391-401. doi: 10.4049/jimmunol.1101421. Epub 2011 Aug 15.
3
Systems biology of vaccination for seasonal influenza in humans.
Nat Immunol. 2011 Jul 10;12(8):786-95. doi: 10.1038/ni.2067.
4
Measuring human T cell responses in blood and gut samples using qualified methods suitable for evaluation of HIV vaccine candidates in clinical trials.
J Immunol Methods. 2011 Jul 29;370(1-2):43-54. doi: 10.1016/j.jim.2011.05.007. Epub 2011 Jun 12.
5
A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers.
J Infect Dis. 2011 Apr 15;203(8):1165-73. doi: 10.1093/infdis/jiq175.
6
Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.
J Infect Dis. 2011 Mar 1;203(5):610-9. doi: 10.1093/infdis/jiq105. Epub 2011 Jan 31.
7
SPICE: exploration and analysis of post-cytometric complex multivariate datasets.
Cytometry A. 2011 Feb;79(2):167-74. doi: 10.1002/cyto.a.21015. Epub 2011 Jan 7.
8
Interpretation of cellular proliferation data: avoid the panglossian.
Cytometry A. 2011 Feb;79(2):95-101. doi: 10.1002/cyto.a.21010. Epub 2011 Jan 12.
9
Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection.
J Exp Med. 2011 Jan 17;208(1):181-93. doi: 10.1084/jem.20101352. Epub 2011 Jan 10.
10
A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects.
Vaccine. 2011 Feb 24;29(10):1948-58. doi: 10.1016/j.vaccine.2010.12.104. Epub 2011 Jan 7.
Zotero 插件